- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06641635
Moderierte hypofraktionierte Online-adaptive Strahlentherapie bei Gebärmutterhalskrebs
Eine multizentrische, nicht unterlegene, randomisierte kontrollierte Phase-3-Studie zur moderierten hypofraktionierten adaptiven Online-Strahlentherapie bei Gebärmutterhalskrebs
The most common external beam radiotherapy fractionation scheme for cervical cancer is 45-50.4 Gy delivered in 25-28 fractions. However, prolonged treatment duration can lead to insufficient availability of medical resources. We hope to assess the safety and efficacy of moderated hypofractionated online adaptive radiotherapy in combination with brachytherapy in patients with cervical cancer in a multicenter study.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
This is a multicenter, non-inferiority, phase 3, randomized controlled study. This study investigates the role of moderated hypofractionated online adaptive radiotherapy by randomizing patients to this experimental regimen versus the standard of treatment.The purpose of this study is to access safety and efficacy of moderated hypofractionated online adaptive radiotherapy in combination with high-dose-rate brachytherapy in patients with cervical cancer, which based on the previous research (NCT05994300).
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
- Name: Zheng Zeng, MD.
- Telefonnummer: 86-10-6512-4875
- E-Mail: zengzheng1206@163.com
Studienorte
-
-
-
Beijing, China
- Rekrutierung
- Peking Union Medical College Hospital
-
Kontakt:
- Junfang Yan, MD
- Telefonnummer: 01069155484
- E-Mail: yanjunfang@pumch.cn
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- The patient is fully voluntary and has the capacity for autonomy, signing the informed consent form 30 days prior to enrollment
- Age ≥18 and ≤75 years
- FIGO 2018 stage IB1-IIB, IIIB cervical cancer; IIIC1 (lymph node metastasis ≤2 cm, without common iliac lymph node metastasis)
- Pathologically diagnosed as squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
- Concurrent weekly cisplatin therapy ± immunotherapy
- Able to undergo brachytherapy
- ECOG performance status of 0-1, with an expected ability to tolerate lying flat for half an hour.
Exclusion Criteria:
- Patients who have undergone cervical cancer surgery
- FIGO stages IA, IIIA, IIIC2, IVA, or IVB
- FIGO stage IIIC1 with lymph nodes >2 cm, or with common iliac lymph node metastasis
- Patients who received other anticancer treatments, including chemotherapy, targeted therapy, or immunotherapy, before concurrent chemoradiotherapy.
- History of prior abdominal or pelvic radiotherapy
- Pregnant or breastfeeding women
- Patients with active infections or fever
- Other severe diseases that may significantly affect clinical trial compliance, such as unstable heart disease, kidney disease, chronic hepatitis requiring treatment, poorly controlled diabetes, or mental disorders.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Experimental group
Moderately hypofractionated online adaptive radiotherapy +Concurrent Chemotherapy or Immunotherapy Experimental |
Radiation: Moderated hypofractionated online adaptive radiotherapy (oART)+ High-dose rate (HDR) Brachytherapy Experimental group: 43.35Gy/17F external beam radiotherapy with oART + HDR-Brachytherapy Drug: Concurrent Chemotherapy or immunotherapy Weekly cisplatin 40 mg/m2 or PD-1 inhibitors |
|
Aktiver Komparator: Control group
Conventionally fractionated intensity-modulated radiotherapy +Concurrent Chemotherapy or Immunotherapy Standard of Care |
Radiation: External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy Contral group: 45Gy/25F EBRT + HDR-Brachytherapy Drug: Concurrent Chemotherapy or immunotherapy Weekly cisplatin 40 mg/m2 or PD-1 inhibitors |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Progression Free Survival
Zeitfenster: 3 years
|
Defined as time from date of randomization to date of progression, date of death from any cause, or date of last follow-up, whichever occurs first. Cancer progression can be identified during physical exam, biopsy, or imaging of any kind. |
3 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Acute toxicity
Zeitfenster: 3 months
|
This outcome is assessed by physicians during each follow-up appointment, and scored according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 . Clinically relevant toxicities of gastrointestinal, genitourinary, vaginal and non-specific general symptoms (i.e. fatigue, malaise and pain) will be collected. Hematological disorders will also be collected through weekly blood work checks. Acute toxicities will be collected at baseline, and then weekly during radiotherapy/chemoradiotherapy and at 3 months after completion of radiation. |
3 months
|
|
Late toxicity
Zeitfenster: 3 years
|
Late toxicities will be collected from 3 months after completion of radiation onwards until the end of follow-up. |
3 years
|
|
Overall survival
Zeitfenster: 3 years
|
Defined as time from date of randomization to date of death from any cause, or date of last follow-up, whichever occurs first. |
3 years
|
|
Quality of life (QoL)
Zeitfenster: 3 years
|
QoL will evaluated by the EORTC QLQ-C30 questionnaire.QLQ-C30 questionnaire is used for all cancers and has several symptom scales, five functional scales (physical, emotional, social, role, cognitive) and a global health status scale. Response options are a four-point Likert scale from "not at all" to "very much" or a seven-point Likert scale from "very poor" to "excellent." |
3 years
|
|
Quality of Life (QoL)
Zeitfenster: 3 years
|
QoL will be measured by the cervical cancer module (QLQ-CX24). QLQ-CX24 includes cancer - and treatment - related items and symptoms regarding sexuality. Acute and late vaginal and sexual QoL will be assessed using the QLQ-CX24 vaginal and sexual domains respectively. The QLQ-CX24 responses are regarding function and symptoms of sexual and vagina health. It is based on a scale of 1 (not at all) to 4 (very much). |
3 years
|
|
Locoregional progression-free survival
Zeitfenster: 3 years
|
Defined as time from date of randomization to date of locoregional progression, date of death from any cause, or date of last follow-up, whichever occurs first. |
3 years
|
|
Tumor response evaluation Complete remission rate
Zeitfenster: 3 months
|
Evaluated with RECIST 1.1 |
3 months
|
|
Metastasis-free survival
Zeitfenster: 3 years
|
Defined as time from date of randomization to date of development of metastasis, date of death from any cause, or date of last follow-up, whichever occurs first. |
3 years
|
|
Cervical cancer-specific survival
Zeitfenster: 3 years
|
Defined as time from date of randomization to date of death attributed to cervical cancer, or date of last-follow-up, whichever occurs first. |
3 years
|
|
Treatment expense
Zeitfenster: 3 months
|
The treatment-related costs incurred during the course of treatment. |
3 months
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Assessment of tumor regression throughout EBRT
Zeitfenster: 3 months
|
To be assessed through volumetric comparison of tumor volume in the pre-EBRT and post-EBRT MRI scans. |
3 months
|
Mitarbeiter und Ermittler
Mitarbeiter
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Genitalerkrankungen
- Urogenitale Neoplasmen
- Neubildungen nach Standort
- Neubildungen
- Weibliche Urogenitalerkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Uteruserkrankungen
- Genitalerkrankungen, weiblich
- Genitale Neubildungen, weiblich
- Gebärmutterhalskrankheiten
- Uterusneoplasmen
- Gebärmutterhalstumoren
Andere Studien-ID-Nummern
- SWIFT-1
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .